One aspect of the present invention relates to novel heterocyclic
compounds. A second aspect of the present invention relates to the use of
the novel heterocyclic compounds as ligands for various mammalian cellular
receptors, including G-protein coupled receptors. A third aspect of the
present invention relates to the use of the novel heterocyclic compounds
as ligands for mammalian dopamine, muscarinic or serotonin receptors or
transporters. Another aspect of the present invention relates to the use
of the novel heterocyclic compounds as ligands for mammalian dopamine,
muscarinic or serotonin receptors. The compounds of the present invention
will also find use in the treatment of numerous ailments, conditions and
diseases which afflict mammals, including but not limited to addiction,
anxiety, depression, sexual dysfunction, hypertension, migraine,
Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia,
Parkinson's disease, restless leg syndrome, sleeping disorders, attention
deficit hyperactivity disorder, irritable bowel syndrome, premature
ejaculation, menstrual dysphoria syndrome, urinary incontinence,
inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's
disease, Tourette's syndrome, psychiatric disorders, stroke, senile
dementia, peptic ulcers, pulmonary obstruction disorders, and asthma.
